|
|
Blood, 15 October 2004, Vol. 104, No. 8, pp. 2353-2358.
Prepublished online as a Blood First Edition Paper on June 29, 2004; DOI 10.1182/blood-2004-01-0145.
 Previous Article | Table of Contents | Next Article 
HEMOSTASIS, THROMBOSIS, AND VASCULAR BIOLOGY
Characterization of monocyte tissue factor activity induced by IgG antiphospholipid antibodies and inhibition by dilazep
Hong Zhou,
Alisa S. Wolberg, and
Robert A. S. Roubey
From the Department of Medicine, Division of Rheumatology and Immunology, University of North Carolina, Chapel Hill; and the Department of Pathology and Laboratory Medicine, University of North Carolina, Chapel Hill.
Increasing evidence suggests that autoantibodies directly contribute to hypercoagulability in the antiphospholipid syndrome (APS). One proposed mechanism is the antibody-induced expression of tissue factor (TF) by blood monocytes. Dilazep, an antiplatelet agent, is an adenosine uptake inhibitor known to block induction of monocyte TF expression by bacterial lipopolysaccharide. In the current study we characterized the effects of immunoglobulin G (IgG) from patients with APS on monocyte TF activity and investigated whether dilazep is capable of blocking this effect. IgG from 13 of 16 patients with APS significantly increased monocyte TF activity, whereas normal IgG had no effect. Time-course experiments demonstrated that APS IgG-induced monocyte TF mRNA levels were maximal at 2 hours and TF activity on the cell surface was maximal at 6 hours. Dilazep inhibited antibody-induced monocyte TF activity in a dose-dependent fashion but had no effect on TF mRNA expression. The effect of dilazep was blocked by theophylline, a nonspecific adenosine receptor antagonist. In conclusion, IgG from certain patients with APS induce monocyte TF activity. Dilazep inhibits the increased expression of monocyte TF activity at a posttranscriptional level, probably by way of its effect as an adenosine uptake inhibitor. Pharmacologic agents that block monocyte TF activity may be a novel therapeutic approach in APS.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
K Oku, T Atsumi, M Bohgaki, O Amengual, H Kataoka, T Horita, S Yasuda, and T Koike
Complement activation in patients with primary antiphospholipid syndrome
Ann Rheum Dis,
June 1, 2009;
68(6):
1030 - 1035.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. K. Farmer-Boatwright and R. A.S. Roubey
Venous Thrombosis in the Antiphospholipid Syndrome
Arterioscler. Thromb. Vasc. Biol.,
March 1, 2009;
29(3):
321 - 325.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y.-H. Yang, D. Chien, M. Wu, J. FitzGerald, J. M. Grossman, B. H. Hahn, K.-K. Hwang, and P. P. Chen
Novel Autoantibodies against the Activated Coagulation Factor IX (FIXa) in the Antiphospholipid Syndrome That Interpose the FIXa Regulation by Antithrombin
J. Immunol.,
February 1, 2009;
182(3):
1674 - 1680.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. A Asherson, S. S Pierangeli, and R. Cervera
Is there a microangiopathic antiphospholipid syndrome?
Ann Rheum Dis,
April 1, 2007;
66(4):
429 - 432.
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. Satta, S. Dunoyer-Geindre, G. Reber, R. J. Fish, F. Boehlen, E. K. O. Kruithof, and P. de Moerloose
The role of TLR2 in the inflammatory activation of mouse fibroblasts by human antiphospholipid antibodies
Blood,
February 15, 2007;
109(4):
1507 - 1514.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Giannakopoulos, F. Passam, S. Rahgozar, and S. A. Krilis
Current concepts on the pathogenesis of the antiphospholipid syndrome
Blood,
January 15, 2007;
109(2):
422 - 430.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Lopez-Pedrera, P Buendia, M A Aguirre, F Velasco, and M J Cuadrado
Antiphospholipid syndrome and tissue factor: a thrombotic couple
Lupus,
March 1, 2006;
15(3):
161 - 166.
[Abstract]
[PDF]
|
|
|
|
|
|
|
T Koike and T Atsumi
Antiphospholipid antibodies and cell activation: crucial role of p38 MAPK pathway
Lupus,
October 1, 2005;
14(10):
799 - 801.
[PDF]
|
|
|
|
|
